Clinical Trial Update: Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLC [Phase 2]

View source ↗

Summary

A Phase 2 trial tests crizotinib against standard chemotherapy in metastatic exon 14 skipping non-small cell lung cancer; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Crizotinib (crizotinib)
• Standard chemotherapy

Snippet

Sponsor: Hunan Province Tumor Hospital | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: RECRUITING